Liquid biopsies revolutionize diagnostics by detecting circulating tumor DNA (ctDNA) and cell-free DNA (cfDNA) in blood, eliminating the need for invasive biopsies. This cutting-edge approach enables early cancer detection, monitors treatment response, and identifies tumor heterogeneity. Advances in fragmentomics and sequencing technologies continue to refine precision oncology.
Advancements in Liquid Biopsies: Analyzing Circulating Tumor DNA
